Skip to main content
. 2018 Jun 15;13:93. doi: 10.1186/s13023-018-0834-2

Fig. 6.

Fig. 6

Adverse events, renal toxicity. Subgroup analysis showed a significant increase in the renal toxicity in the drisapersen group, but not in the eteplirsen group, compared with that in the placebo groups